🔎 Under the Radar: Kodiak Stock Surges as Eye Drug Matches Regeneron’s

Kodiak Sciences shares surged more than 170% Monday, marking the company's largest single-day gain on record, after announcing its eye drug matched the efficacy of Regeneron's blockbuster treatment Eylea in a Phase 3 trial. The Palo Alto, California-based biotech reported that more than half of patients in the study achieved the primary endpoint, putting its experimental therapy on par with one of the leading drugs in the retinal disease market.

The result validates Kodiak's development program and positions the company to compete in the multibillion-dollar market for treatments targeting wet age-related macular degeneration and diabetic retinopathy, conditions currently dominated by Regeneron's Eylea. The magnitude of Monday's move reflects the binary risk biotech investors faced ahead of the data release—Phase 3 trials either clear the path to commercialization or destroy shareholder value.

Regeneron's Eylea generated billions in annual sales, establishing a benchmark for efficacy that new entrants must meet to gain regulatory approval and payer acceptance. Kodiak's ability to match that standard removes a major hurdle, though commercial success will depend on differentiation factors such as dosing frequency, safety profile, and pricing strategy.